- |||||||||| Zortress (everolimus) / Novartis, tacrolimus / Generic mfg.
Retrospective data, Journal: Viremia Negativization After BK Virus Infection in Kidney Transplantation: A National Bicentric Study. (Pubmed Central) - Jan 28, 2020 Early BKV diagnosis and stepwise minimization of immunosuppression remain the first-line approach in patients with BK viremia. In the presence of BKV nephropathy, a combination of antiviral drugs like leflunomide and fluoroquinolones/everolimus should favor viremia clearance.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Retrospective data, Review, Journal: Efficacy and safety of systemic treatments in psoriatic arthritis. A systematic review, meta-analysis and GRADE evaluation. (Pubmed Central) - Jan 17, 2020 Besides the established treatment of anti TNF antibodies und ustekinumab for psoriatic arthritis, the newer treatment options of IL17 antibodies and apremilast are also effective for the treatment of psoriatic arthritis. Based on just one comparative trial and one drug each, the new class of anti IL 17 antibodies appears to be equally effective as the group of anti TNF antibodies, for apremilast this is yet unclear.
- |||||||||| teriflunomide / Generic mfg., leflunomide / Generic mfg.
Journal: Dihydroorotate dehydrogenase inhibitors in anti-infective drug research. (Pubmed Central) - Jan 16, 2020 Dihydroorotate dehydrogenase (DHODH), which is involved in the de novo biosynthesis of pyrimidines, is a validated target for anti-infective drug research. Recent advances in the DHODH microorganism field are discussed herein, as is the potential for the development of DHODH-targeted therapeutics.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J
Biomarker, Clinical, Journal: Proteomic analysis of biomarkers predicting the response to triple therapy in patients with rheumatoid arthritis. (Pubmed Central) - Jan 15, 2020 Recent advances in the DHODH microorganism field are discussed herein, as is the potential for the development of DHODH-targeted therapeutics. This study demonstrated the feasibility of exploring biomarkers by applying iTRAQ and PRM mass spectrometry techniques, and a panel of biomarkers were identified to predict clinical response of IFX + MTX + LEF treatment in active RA patients.
- |||||||||| tacrolimus / Generic mfg., cyclophosphamide intravenous / Generic mfg., Rituxan (rituximab) / Roche, Biogen
Retrospective data, Journal: Effectiveness and safety of common therapeutic drugs for refractory lupus nephritis: A network meta-analysis. (Pubmed Central) - Jan 5, 2020 There were no statistically significant differences in adverse reactions, including gastrointestinal reactions and leukopenia between any two treatment regimens. In conclusion, the regimen of CTX + TAC + GC exhibited a trend in superiority regarding clinical efficacy among common therapeutic drug treatments for RLN, while the regimen of CTX + GC had a higher probability to cause adverse effects among the nine interventions compared.
- |||||||||| leflunomide / Generic mfg.
Journal: Protective effects of vitamin D and losartan in complete Freund's adjuvant-induced arthritis in rats. (Pubmed Central) - Jan 4, 2020 The remaining three groups (III, IV, V) were given CFA followed by treatment with leflunomide, vitamin D or losartan, respectively for two weeks...It could be concluded that vitamin D and losartan are able to repress the alterations associated with adjuvant-induced arthritis (AIA). This preserving effect might be partially attributed to antiarithritic, hypolipidemic and antianemic properties.
|